Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/ mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

Documenti analoghi

• Efficacy and safety of insulin glargine 300 U/ mL in people with type 2 diabetes in China: The INITIATION study
  di: Liming Chen, et al.
  Pubblicazione: (2024)
• Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis
  di: Pierre Gourdy, et al.
  Pubblicazione: (2024)
• Insulin glargine 300 U/ mL safety data in pregnancy
  di: Jukka Westerbacka, et al.
  Pubblicazione: (2025)
• Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
  di: Jochen Seufert, et al.
  Pubblicazione: (2024)
• The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
  di: Yiming Mu
  Pubblicazione: (2024)